Shanghai WuXi Zhangjiang Biopharmaceuticals

WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides comprehensive, end-to-end solutions for biologics discovery, development, and manufacturing. The company operates a massive R&D and manufacturing network, with a significant presence in the Zhangjiang Hi-Tech Park in Shanghai. WuXi Biologics utilizes proprietary technology platforms such as WuXiBody for bispecific antibodies and WuXiUP for continuous manufacturing to accelerate the development of therapeutic proteins, vaccines, and gene therapies. As a publicly traded entity on the Hong Kong Stock Exchange, it supports hundreds of active projects for pharmaceutical and biotech partners worldwide, ranging from early-stage research to commercial-scale production. The company is recognized for its "Follow-the-Molecule" strategy, which ensures long-term partnerships as client assets progress through clinical trials to the market.